Curated News
By: NewsRamp Editorial Staff
October 05, 2026
NHS Deploys Rapid Brain Tumor Test, Cutting Diagnosis to 2 Hours
TLDR
- The University of Nottingham and NHS have deployed a two-hour brain tumor genetic test, gaining a significant diagnostic speed advantage over the previous eight-week wait.
- The Brain Tumor Research Center of Excellence at the University of Nottingham developed the tool, which analyzes a tumor's genetic makeup during surgery, and the NHS has begun using it.
- Patients with brain tumors can now receive a rapid genetic diagnosis, reducing anxiety and enabling earlier access to treatments from companies like CNS Pharmaceuticals Inc.
- A new brain tumor test can reveal genetic details in about two hours, compared to the old eight-week wait, potentially transforming surgical decision-making.
Impact - Why it Matters
The ability to determine a brain tumor’s genetic profile in about two hours instead of eight weeks is a seismic shift in neuro-oncology. It means patients can begin targeted therapies almost immediately, potentially improving outcomes and survival rates. For biotech firms like CNS Pharmaceuticals, faster diagnosis could accelerate patient access to experimental treatments and clinical trials, creating a more efficient pathway from diagnosis to care. This innovation underscores the growing synergy between advanced diagnostics and precision medicine, offering hope to thousands facing brain tumors.
Summary
Surgeons at the University of Nottingham’s Brain Tumor Research Center of Excellence have developed a groundbreaking tool that identifies a brain tumor’s genetic makeup during surgery, slashing diagnosis time from eight weeks to about two hours. The NHS has already started using the test, which allows doctors to make real-time decisions about treatment while the patient is still on the operating table. This rapid diagnostic capability promises to transform brain tumor care by enabling more precise and timely interventions.
As diagnostic tools for brain tumors improve, patients may soon benefit from therapies being developed by biotech companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) once treatment begins. The news was highlighted by TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio @ IBN, which offers services such as access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and a full array of tailored corporate communications solutions. TinyGems aims to serve private and public companies seeking wide audience reach.
For more information, visit https://www.TinyGems.com. To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only). TinyGems is powered by IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NHS Deploys Rapid Brain Tumor Test, Cutting Diagnosis to 2 Hours
